ATE255882T1 - Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren - Google Patents

Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren

Info

Publication number
ATE255882T1
ATE255882T1 AT98930447T AT98930447T ATE255882T1 AT E255882 T1 ATE255882 T1 AT E255882T1 AT 98930447 T AT98930447 T AT 98930447T AT 98930447 T AT98930447 T AT 98930447T AT E255882 T1 ATE255882 T1 AT E255882T1
Authority
AT
Austria
Prior art keywords
liposomes
polynucleotide composition
polynucleotide
liposome
composition
Prior art date
Application number
AT98930447T
Other languages
German (de)
English (en)
Inventor
Theresa M Allen
Darrin Stuart
Original Assignee
Sequus Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharm Inc filed Critical Sequus Pharm Inc
Application granted granted Critical
Publication of ATE255882T1 publication Critical patent/ATE255882T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98930447T 1997-06-23 1998-06-22 Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren ATE255882T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5049097P 1997-06-23 1997-06-23
PCT/US1998/012937 WO1998058630A1 (en) 1997-06-23 1998-06-22 Liposome-entrapped polynucleotide composition and method

Publications (1)

Publication Number Publication Date
ATE255882T1 true ATE255882T1 (de) 2003-12-15

Family

ID=21965541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930447T ATE255882T1 (de) 1997-06-23 1998-06-22 Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren

Country Status (11)

Country Link
US (1) US6120798A (https=)
EP (1) EP1017365B1 (https=)
JP (1) JP2002508765A (https=)
AT (1) ATE255882T1 (https=)
AU (1) AU7983798A (https=)
CA (1) CA2294579C (https=)
DE (1) DE69820465T2 (https=)
DK (1) DK1017365T3 (https=)
ES (1) ES2212305T3 (https=)
TW (1) TWI225412B (https=)
WO (1) WO1998058630A1 (https=)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
JP2002536316A (ja) * 1999-02-08 2002-10-29 アルザ・コーポレーション リポソームサイズを調節する方法
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US20020146829A1 (en) * 2000-11-29 2002-10-10 Aventis Pharmaceuticals Products Inc. Neutral and anionic colloidal particles for gene delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer
KR100466254B1 (ko) * 2002-02-25 2005-01-14 한국과학기술원 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
EP1530465B2 (en) * 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2002953285A0 (en) * 2002-12-12 2003-01-02 Protech Research Pty Ltd Yeast treatment
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP2353389B1 (en) 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Compositions for treating disorders
EP1765294B1 (en) * 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
EP1970078A4 (en) 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd COMPOSITION FOR INHIBITING A TARGET GENE IN AN EYEBORN AND REMEDY FOR ACAPIC DISEASE
EP2162552A4 (en) 2007-05-11 2010-06-30 Univ Johns Hopkins BIOMARKER FOR MELANOME
PL208054B1 (pl) * 2007-09-06 2011-03-31 Akademia Medyczna Im Piastow Śląskich We Wrocławiu Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
CA2710983A1 (en) * 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
CN105030809A (zh) 2008-08-01 2015-11-11 协和发酵麒麟株式会社 抑制靶基因表达的组合物
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
PL2474306T3 (pl) 2009-08-31 2017-06-30 Nanocarrier Co., Ltd. Kompozycja w postaci cząstek stałych i zawierająca ją kompozycja lecznicza
JP4653242B1 (ja) 2010-02-12 2011-03-16 ナノキャリア株式会社 粒子状医薬組成物
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
WO2011136369A1 (ja) 2010-04-28 2011-11-03 協和発酵キリン株式会社 カチオン性脂質
KR101773643B1 (ko) 2010-04-28 2017-08-31 교와 핫꼬 기린 가부시키가이샤 양이온성 지질
CN103119160B (zh) 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
JP5952197B2 (ja) 2011-01-19 2016-07-13 協和発酵キリン株式会社 標的遺伝子の発現を抑制する組成物
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
US9631192B2 (en) 2011-11-17 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)
AU2012340086A1 (en) 2011-11-17 2014-05-29 The Regents Of The University Of California Therapeutic RNA switches compositions and methods of use
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
KR20140111272A (ko) 2011-12-12 2014-09-18 교와 핫꼬 기린 가부시키가이샤 양이온성 지질의 조합을 함유하는 지질 나노 입자
US9556432B2 (en) 2012-01-10 2017-01-31 The Research Foundation For The State University Of New York Method of treating hyperlipidemia and atherosclerosis with miR-30C
AU2013237874B2 (en) 2012-03-29 2018-01-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
EP2852380A4 (en) 2012-05-23 2016-01-20 Univ Ohio State LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF
US10502737B2 (en) 2012-05-25 2019-12-10 The University Of Vermont And State Agriculture College Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
TW201408625A (zh) 2012-07-06 2014-03-01 Kyowa Hakko Kirin Co Ltd 陽離子性脂質
CA2878314A1 (en) 2012-07-16 2014-01-23 Kyowa Hakko Kirin Co., Ltd. Rnai pharmaceutical composition for suppressing expression of kras gene
JP6000033B2 (ja) * 2012-09-18 2016-09-28 株式会社ピカソ美化学研究所 内包物質に耐熱性を与えたリポソーム及びその製造方法
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
US11174484B2 (en) 2015-11-10 2021-11-16 B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US11998540B2 (en) 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
CA3009131C (en) 2015-12-25 2024-06-04 Kyowa Hakko Kirin Co., Ltd. Compounds as cationic lipids and their use in nucleic acid delivery compositions
JP7522038B2 (ja) 2018-04-06 2024-07-24 ザ チルドレンズ メディカル センター コーポレーション 体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
IL294441A (en) * 2019-12-31 2022-09-01 Fred Hutchinson Cancer Center Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
JP2023530234A (ja) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物を治療するための組成物および方法
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
WO2024226499A1 (en) 2023-04-24 2024-10-31 The Broad Institute, Inc. Compositions and methods for modifying fertility
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5976567A (en) * 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique

Also Published As

Publication number Publication date
CA2294579A1 (en) 1998-12-30
DK1017365T3 (da) 2004-03-29
HK1025906A1 (en) 2000-12-01
EP1017365A1 (en) 2000-07-12
JP2002508765A (ja) 2002-03-19
WO1998058630A1 (en) 1998-12-30
EP1017365B1 (en) 2003-12-10
AU7983798A (en) 1999-01-04
TWI225412B (en) 2004-12-21
DE69820465T2 (de) 2004-09-16
DE69820465D1 (de) 2004-01-22
US6120798A (en) 2000-09-19
ES2212305T3 (es) 2004-07-16
CA2294579C (en) 2007-10-09

Similar Documents

Publication Publication Date Title
ATE255882T1 (de) Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren
PT76245B (de) Verfahren zur herstellung von unilamellaren liposomen in waessriger phase
CA2191077A1 (en) Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
DE69529225D1 (de) Verfahren zur herstellung dopppelschichtiger lipidmembranen
ES2152324T3 (es) Vesiculas lipidicas multilaminares bifasicas.
ES8205441A1 (es) Un metodo de fabricar una lamina de papel tisu de multiples capas tendida en humedo.
KR890700339A (ko) 포오시라멜라 지질소포
CA2270396A1 (en) Cationic reagents for transfection
AU2002301268A1 (en) Production of multivesicular liposomes
DE3482161D1 (de) Zubereitung von arzneimittelhaltigen lipidvesikeln und verfahren zu deren herstellung.
IL115849A0 (en) Tangential filtration preparation of liposomal drugs and liposome product thereof
NZ503568A (en) Biphasic lipid vesicle composition for transdermal administration of an immunogen
IL142573A0 (en) Liposome-entrapped topoisomerase inhibitors
CA2148311A1 (en) Lipid Vesicles, Their Process of Production and Their Applications
DK0671904T3 (da) Antibiotisk præparat og anvendelse mod lægemiddelresistente infektioner
EP0757431A3 (en) Machine structure consisting of a large number of microstructure layers
IE830690L (en) Stable plurilamellar vesicles
ATE223205T1 (de) Verfahren zur herstellung von liposomen, die hydrophobische artzneistoffe enthalten
EP1042423A4 (en) PROCESS FOR FORMING ANTI-CORROSION LAYERS WITH HYDROGEN BENZOTRIAZOLE DERIVATIVES
FI873111L (fi) Menetelmä yksittäisten kaksikerroksisten liposomien valmistamiseksi
EP0787853A4 (en) THREE-DIMENSIONAL PRINTED FABRIC AND ITS MANUFACTURING METHOD
AU1753497A (en) Sol-gel encapsulation of lipid vesicles, lipid membranes and proteins
EP0198765A3 (en) Preparation of liposomes
AU5167685A (en) Polymerisable liposome-forming lipids
CA2346016A1 (en) Glucoside paucilamellar vesicles

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties